(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/210082 A1

(51) International Patent Classification:
C07K 16/00 (2006.01) *A61K 39/00* (2006.01)
C07K 16/42 (2006.01)

(21) International Application Number:
PCT/EP2025/058977

(22) International Filing Date:
02 April 2025 (02.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2404869.6	05 April 2024 (05.04.2024)	GB
2409026.8	24 June 2024 (24.06.2024)	GB

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; Allée de la Recherche 60, 1070 Brussels (BE).

(72) Inventors: **ANTONYUK, Svetlana**; c/o University of Liverpool, Foundation Building, Brownlow Hill, Liverpool L69 7ZX (GB). **CRABBE, Thomas Bartholomew**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **GALMICHE, Cecile Lucie**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **MADINE, Jillian**; c/o University of Liverpool, Foundation Building, Brownlow Hill, Liverpool L69 7ZX (GB). **MAERIVOET, Alana**; c/o University of Liverpool, Foundation Building, Brownlow Hill, Liverpool L69 7ZX (GB). **SCOTT-TUCKER, Anthony**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(74) Agent: **UCB INTELLECTUAL PROPERTY**; c/o UCB, 208 Bath road, Slough Berkshire SL1 3WE (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: HEAVY CHAIN VARIABLE DOMAINS THAT BIND TO FREE LIGHT CHAINS

(57) Abstract: The present invention relates to antibodies binding to, or pairing with, free light chains, such as free kappa light chains and/or (kappa) amyloidogenic light chains, and formulations comprising the same. The invention further relates to the use of the anti-light chain antibodies and formulations in therapy and/or diagnosis.

WO 2025/210082 A1